Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N.
Senapati J, et al. Among authors: wilson nr.
Clin Cancer Res. 2023 Nov 1;29(21):4352-4360. doi: 10.1158/1078-0432.CCR-23-1429.
Clin Cancer Res. 2023.
PMID: 37585491